Cortecs International launches novel migraine treatment in the U.K.LONDON--(BUSINESS WIRE)--Oct. 21, 1996--Cortecs International (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DLVRY / LSE LSE - Language Sensitive Editor :COR / ASX ASX See: Australian Stock Exchange :CRI CRI constant-rate infusion. ) today announced that it has launched Clotam(TM) in the U.K. Clotam(TM) is an anti-migraine product licensed from GEA Ltd., a subsidiary of Bristol Myers Squibb. Cortecs' agreement also covers Eire. Clotam(TM) is an NSAID NSAID: see nonsteroidal anti-inflammatory drug. (non-steroidal anti-inflammatory drug Non-steroidal anti-inflammatory drugs, usually abbreviated to NSAIDs, are drugs with analgesic, antipyretic and anti-inflammatory effects - they reduce pain, fever and inflammation. ) which is marketed in 35 countries and has a full U.K. product license approval for acute migraine. It acts in a novel way to inhibit the synthesis of prostaglandins and leukotrienes Leukotrienes A class of small molecules produced by cells in response to allergen exposure; they contribute to allergy and asthma symptoms. Mentioned in: Leukotriene Inhibitors leukotrienes . Incidence of side effects, including gastric side effects, is low. The drug will be available on prescription only and provides practitioners with an alternative cost-effective approach to the treatment and prevention of acute migraine. The treatment regime is one capsule at the first signs of migraine repeated after two to three hours. Each capsule costs one pound sterling. In the U.K., it is estimated that migraine affects 10% of the population, with women being three times more prone to attacks than men. Acute migraine causes an estimated loss of U.K. working days of between 3.2 to 6.4 million every year and the U.K. market for treatments for the condition is approximately no. 46 million a year. Dr. Geoffrey Hill, Managing Director of Cortecs Limited, said: "Product sales make up the majority of Cortecs' turnover. I believe Clotam(TM) will be a significant new product in Cortecs' portfolio." He added: "Cortecs has also last week introduced a new food diagnostic kit to detect peanut protein in food. Peanut protein can cause anything from a mild swelling in the mouth to death from anaphylactic shock in very sensitive individuals. The product is intended for food manufacturers and Public Analysts who need to assess individual commodities and processed foods for the presence of this protein for quality control and labeling purposes. Cortecs intends to exploit the world-wide market for this product. While the market for this test may not be very significant, it further demonstrates the Company's commitment to addressing unmet needs in the healthcare industry." Cortecs International is a British-based company quoted on the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. , the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. and on Nasdaq. The Company specializes in the development of new pharmaceutical delivery systems and point-of-care rapid diagnostics which provide the opportunity to advance the management of serious diseases such as: OSTEOPOROSIS -- Oral Calcitonin calcitonin /cal·ci·to·nin/ (-to´nin) a polypeptide hormone secreted by C cells of the thyroid gland, and sometimes of the thymus and parathyroids, which lowers calcium and phosphate concentration in plasma and inhibits bone resorption. - an oral therapy for the prevention of bone breakdown. In Phase II/III. -- Osteosal - a rapid doctors' office test in collaboration with Osteometer to detect increased bone breakdown indicating the risk of the disease osteoporosis and also to monitor the adequacy of therapy. In development. HELICOBACTER PYLORI -- Helisal - a rapid doctors' office whole blood test for the detection of H. pylori. In the market. A rapid saliva test in development. A 'one step' whole blood test for the detection of H. pylori. In development. -- Oral Therapeutic Vaccine in development to stimulate immunity. -- Oral Therapeutic in research to improve eradication results. DIABETES -- Glycosal - Three rapid doctors' office test in collaboration with Exocell to assist in the management and identification of diabetics. In development. -- Oral Insulin - In Phase I trials. CYSTIC FIBROSIS & CHRONIC BRONCHITIS -- Pseudostat - oral therapeutic antigens to treat and prevent lung infection with Pseudomonas aeruginosa now in Phase II trials. INFLUENZA Flustat - an oral vaccine against influenza. Entering human trials in 1996. THRUSH Moniliastat - an oral therapeutic vaccine against vaginal thrush. Enters human trials in 1996. MALE HORMONE DEFICIENCY -- Halo Testosterone - an oral male hormone replacement therapy Hormone Replacement Therapy Definition Hormone replacement therapy (HRT) is the use of synthetic or natural female hormones to make up for the decline or lack of natural hormones produced in a woman's body. in development to treat male hypogonadism. Cortecs also markets a range of ethical and OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). medicines and diagnostic products. NOTE TO EDITORS: Press releases and other Cortecs International Limited information are available on the Cortecs International Limited web site: http://www.cortecs.com. CONTACT: Cortecs Limited Dr. Geoffrey Hill, Managing Director 012 44-288-781 or Kehoe, White, Savage & Company, Inc. John P. Kehoe/Van Negris (212) 888-1616 or Buchanan Communications Zena Bates 011 44 171 489 1441 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion